Allianz Asset Management GmbH trimmed its position in Heska Corp (NASDAQ:HSKA) by 11.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 71,369 shares of the medical research company’s stock after selling 8,933 shares during the period. Allianz Asset Management GmbH owned about 0.99% of Heska worth $6,287,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Heska by 31.7% in the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock worth $47,141,000 after buying an additional 111,232 shares during the period. Dimensional Fund Advisors LP raised its stake in Heska by 115.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock valued at $12,266,000 after purchasing an additional 64,418 shares during the period. Geneva Advisors LLC raised its stake in Heska by 565.4% during the 2nd quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock valued at $7,706,000 after purchasing an additional 64,153 shares during the period. Fred Alger Management Inc. raised its stake in Heska by 133.8% during the 2nd quarter. Fred Alger Management Inc. now owns 97,229 shares of the medical research company’s stock valued at $9,924,000 after purchasing an additional 55,647 shares during the period. Finally, Marshall Wace North America L.P. bought a new stake in Heska during the 2nd quarter valued at approximately $4,847,000. 80.89% of the stock is currently owned by institutional investors and hedge funds.
Shares of Heska Corp (NASDAQ:HSKA) traded up $2.23 during trading on Thursday, hitting $81.07. The stock had a trading volume of 54,125 shares, compared to its average volume of 52,566. The stock has a market cap of $579.10, a PE ratio of 42.67, a price-to-earnings-growth ratio of 2.02 and a beta of 0.74. Heska Corp has a 12-month low of $74.21 and a 12-month high of $115.00.
Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The company had revenue of $31.40 million during the quarter, compared to analysts’ expectations of $36.10 million. During the same quarter in the previous year, the business earned $0.45 EPS. Heska’s revenue was down 6.0% compared to the same quarter last year. equities analysts anticipate that Heska Corp will post 2.03 earnings per share for the current fiscal year.
Several brokerages recently issued reports on HSKA. BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Zacks Investment Research cut Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Aegis restated a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial restated a “buy” rating on shares of Heska in a report on Monday, December 4th. Finally, B. Riley cut their price target on Heska from $96.50 to $93.00 and set a “neutral” rating for the company in a report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Heska presently has an average rating of “Hold” and an average target price of $113.30.
In related news, insider Michael J. Mcginley sold 7,826 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the completion of the transaction, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 14.70% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/heska-corp-hska-shares-sold-by-allianz-asset-management-gmbh.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.